Enhanced pathogenicity of Th17 cells due to natalizumab treatment: Implications for MS disease rebound.

导出 OA

翻译打印收藏纠错

作者： Claudia,Janoschka ^[1] ; Maren,Lindner ^[1] ; Nils,Koppers ^[2] ; Laura,Starost ^[3] ; Marie,Liebmann ^[1] ; Melanie,Eschborn ^[1] ; Tilman,Schneider-Hohendorf ^[1] ; Farina,Windener ^[3] ; David,Schafflick ^[1] ; Ann-Katrin,Fleck ^[1] ; Kathrin,Koch ^[1] ; Marie,Deffner ^[1] ; Anna-Sophie,Schwarze ^[1] ; Andreas,Schulte-Mecklenbeck ^[1] ; Imke,Metz ^[4] ; Sven G,Meuth ^[5] ; Catharina C,Gross ^[1] ; Gerd,Meyer Zu Hörste ^[1] ; Nicholas,Schwab ^[1] ; Tanja,Kuhlmann ^[3] ; Heinz,Wiendl ^[1] ; Monika,Stoll ^[2] ; Luisa,Klotz ^[1]

作者单位： Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster 48149, Germany. ^[1] Institute of Human Genetics, Genetic Epidemiology, University of Münster, Münster, 48149, Germany. ^[2] Institute for Neuropathology, University of Münster, Münster, 48149, Germany. ^[3] Institute of Neuropathology, University Medical Center, Georg August University, Göttingen, 37073, Germany. ^[4] Department of Neurology, University Hospital Düsseldorf, Düsseldorf, 40225, Germany. ^[5]

关键词 Th17 cells disease rebound multiple sclerosis natalizumab pathogenicity

主题词动物(Animals);小鼠(Mice);Th17细胞(Th17 Cells);毒力(Virulence);多发性硬化(Multiple Sclerosis);脑(Brain)

DOI 10.1073/pnas.2209944120

PMID 36574650

发布时间 2023-02-22

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交